Assay In Which An Enzyme Present Is A Label Patents (Class 435/7.9)
  • Patent number: 10775373
    Abstract: The present invention provides a method for enhancement of the uniform reaction on the porous materials. Comparing with the conventional Western blotting method, the present invention is successfully demonstrated capability on increasing the immune-detection signal intensity and only needs one order of magnitude less of the processing time by applying two orders of magnitude less dosage usage-amount compared to those operated in the conventional method.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: September 15, 2020
    Assignee: NATIONAL TAIWAN UNIVERSITY
    Inventors: An-Bang Wang, Shih-Chung Chang, Chao-Yuan Liu, Yi-Wei Jiang, Yi-Kuang Yen
  • Patent number: 10775386
    Abstract: Provided herein are methods for detecting neutralizing antibodies to leptins, including metreleptin, as well as identifying subjects having such neutralizing antibodies.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: September 15, 2020
    Assignee: Aegerion Pharmaceuticals, Inc.
    Inventor: Jeffrey Sailstad
  • Patent number: 10752681
    Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: August 25, 2020
    Assignee: Rani Therapeutics, LLC
    Inventor: Mir Imran
  • Patent number: 10745744
    Abstract: The disclosed Hi-C protocol can identify genomic loci that are spatially co-located in vivo. These spatial co-locations may include, but are not limited to, intrachromosomal interactions and/or interchromosomal interactions. Hi-C techniques may be applied to many different scales of interest. For example, on a large scale, Hi-C techniques can be used to identify long-range interactions between distant genomic loci.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: August 18, 2020
    Assignees: University of Massachusetts, Massachusetts Institute of Technology, President and Fellows of Harvard College, Whitehead Institute for Biomedical Research
    Inventors: Job Dekker, Erez Lieberman Aiden, Nynke Van Berkum, Andreas Gnirke, Eric Lander, Chad Nusbaum, Louise Williams, Alexandre Melnikov, Georgia Giannoukos
  • Patent number: 10705085
    Abstract: Disclosed are compositions and methods for the use of lipoplex nanoparticle chips and arrays in the detection of/diagnosis of a disease or condition.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: July 7, 2020
    Assignee: Ohio State Innovation Foundation
    Inventors: Ly James Lee, Kwang Joo Kwak, Bo Yu, Yun Wu, Andrew Lee
  • Patent number: 10639329
    Abstract: Novel adoptive immunotherapy compositions comprising co-cultured lentiviral vector-transduced autologous antigen presentation cells and T cells are provided herein as well as are methods of use of same in a patient-specific combination immunotherapy that can be used to treat cancers and other diseases and conditions.
    Type: Grant
    Filed: June 12, 2016
    Date of Patent: May 5, 2020
    Assignee: LENTIGEN TECHNOLOGY, INC.
    Inventors: Boro Dropulic, Rimas Orentas, Dina Schneider, Winfried Krueger
  • Patent number: 10564152
    Abstract: Methods for detecting antigen-specific antibodies in a biological sample are described. The disclosed methods can be used for the diagnosis of a variety of autoimmune and infectious diseases. The methods use a neodymium magnet to efficiently isolate immune complexes. The disclosed methods are rapid, highly specific and sensitive, require very small volumes of biological sample, and do not require the use of radioactivity. With these advantageous features, the disclosed methods are amendable for point-of-care testing (POCT), which is currently not available for the detection of autoantibodies associated with autoimmune disease or for the detection of many pathogen-specific antibodies.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: February 18, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventor: Peter D. Burbelo
  • Patent number: 10473566
    Abstract: Systems and methods for collecting blood and other liquid samples. A sample holder may include a cap and porous element arranged to receive a blood or other liquid sample. The porous element may be stored in a sealed container, e.g., immediately after blood sample collection, and the sample dried while sealed in the container.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: November 12, 2019
    Assignee: Covaris, Inc.
    Inventors: James A. Laugharn, Jr., Hans-Ulrich Thomann
  • Patent number: 10448514
    Abstract: A method produces a conductive paste comprising 15-20% by weight of PDMS and 80-85% by weight of metallic micro-nano particles, wherein the conductive paste is obtained by repeated addition of singular doses of PDMS to a heptane diluted PDMS low viscosity liquid containing the metallic micro-nano particles, wherein the heptane fraction is allowed to evaporate after addition of each of the singular doses of PDMS. A method forms a conductive path on a support layer, wherein the conductive path is encapsulated by an encapsulation layer comprising at least one via through which at least one portion of the conductive path is exposed, the method comprising filling the at least one via with the conductive paste.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: October 15, 2019
    Assignee: Ecole Polytechnique Federale De Lausanne (EPFL)
    Inventors: Ivan Rusev Minev, Stephanie P. Lacour
  • Patent number: 10436786
    Abstract: The present invention provides compositions and methods for detecting the activation states of components of signal transduction pathways in tumor cells. Information on the activation states of components of signal transduction pathways derived from use of the invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: October 8, 2019
    Assignee: Société Des Produits Nestlé S.A.
    Inventors: Sharat Singh, Jeanne Harvey, Phillip Kim, Xinjun Liu, Limin Liu, Robert Barham, Bruce Neri
  • Patent number: 10393632
    Abstract: The present invention contemplates use of encapsulated aqueous and non-aqueous reagents, solutions and solvents and their use in laboratory procedures. These encapsulated aqueous or non-aqueous reagents, solutions and solvents can be completely contained or encapsulated in microcapsules or nanocapsules that can be added to an aqueous or non-aqueous carrier solution or liquid required for medical and research laboratory testing of biological or non-biological specimens.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: August 27, 2019
    Inventor: Lee H. Angros
  • Patent number: 10379117
    Abstract: Device for use in a biosensor comprising a multisite array of test sites, the device being useful for modulating the binding interactions between a (biomolecular) probe or detection agent and an analyte of interest from a biological by modulating the pH or ionic gradient near the electrodes in such biosensor. The device provides a biosensor which is more accurate, reliable and the results of which are more reproducible. Analytic methods for more accurately measuring an analyte of interest in a biological sample are also provided.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: August 13, 2019
    Assignee: Robert Bosch GmbH
    Inventors: Nadezda Fomina, Christopher Johnson, Sam Kavusi, Habib Ahmad
  • Patent number: 10345309
    Abstract: The present invention provides biological markers associated with gastric cancer. In particular, the present invention provides a method of diagnosing gastric cancer (GC) in a subject, the method including: measuring an expression level of one or more proteins in the subject, wherein the one or more proteins are selected from the group consisting of vitamin D binding protein (VDBP), clusterin, insulin like growth factor binding protein complex acid labile subunit (IGFALS), and afamin; comparing the expression level of the or each protein in the subject to a reference expression level for the or each protein; and diagnosing GC in the subject on the basis of the comparison.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: July 9, 2019
    Assignee: Adelaide Research & Innovation Pty Ltd
    Inventors: Peter Hoffmann, Megan Penno, Matthias Robert Walter Ernst
  • Patent number: 10337050
    Abstract: The invention relates to methods, compositions, devices, systems and kits as described including, without limitation, reagents and mixtures for determining the identity of nucleic acids in nucleotide sequences using, for example, sequencing by synthesis methods. In particular, the present invention contemplates the use of polyphenolic compounds, known as antioxidant additives, to improve the efficiency of Sequencing-By-Synthesis reactions. For example, gallic acid (GA) is shown herein to be one of many exemplary SBS polyphenolic additives.
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: July 2, 2019
    Assignee: Qiagen Sciences, LLC
    Inventors: Jerzy Olejnik, Michel Georges Perbost
  • Patent number: 10317403
    Abstract: The present invention provides an immunoassay analyzer capable of discriminating between normal coloring due to a specific immunoreaction and abnormal coloring due to a cause other than the specific immunoreaction in a measurement region of a sample analysis tool. An immunoassay analyzer 1 of the present invention includes an optical detection unit 4 and a determination unit 5. The optical detection unit 4 includes an optical signal measurement unit for measuring an optical signal at each of two or more different wavelengths including a main wavelength for detecting color change due to the specific immunoreaction and a sub-wavelength(s) other than the main wavelength. The determination unit 5 includes a discrimination unit for comparing the respective optical signals at the two or more different wavelengths and discriminating between the color change due to the specific immunoreaction and color change due to a cause other than the specific immunoreaction based on a comparison criterion determined previously.
    Type: Grant
    Filed: February 1, 2013
    Date of Patent: June 11, 2019
    Assignee: ARKRAY, Inc.
    Inventor: Kyouichi Ohshiro
  • Patent number: 10280443
    Abstract: Disclosed is a method for purifying a target protein, comprising steps of: bringing a fusion protein containing an amino acid sequence of a peptide tag, an amino acid sequence of a cleavable site of a protease and an amino acid sequence of a target protein, into contact with the protease in a solution, to cleave the peptide tag from the fusion protein; and bringing the solution containing the peptide tag, the target protein and the protease into contact with an ion exchange resin to separate the target protein and the peptide tag, thereby acquiring a solution containing the target protein, wherein, in the fusion protein, the amino acid sequence of a cleavable site of the protease exists between the amino acid sequence of the peptide tag and the amino acid sequence of the target protein, and the peptide tag is polyanionic or polycationic.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: May 7, 2019
    Assignee: SYSMEX CORPORATION
    Inventor: Ryo Takahashi
  • Patent number: 10267811
    Abstract: The present invention provides a rapid, sensitive method for forensic drug testing in a post-mortem subject using oral fluid collected from the post-mortem subject. The method comprises collecting a sample of oral fluid from a post-mortem subject, analyzing the oral fluid sample qualitatively to detect the presence of one or more non-naturally occurring drugs, analyzing the oral fluid sample quantitatively to determine concentration of the one or more non-naturally occurring drugs in the post-mortem subject, and identifying the one or more non-naturally occurring drugs in the post-mortem subject. The detection and quantification in oral fluid is more sensitive and faster than detection and quantification of the non-naturally occurring drugs in blood, urine, bile, and liver tissue collected from the same post-mortem subject. Further, the qualitative and quantitative results are obtained in as little as three hours.
    Type: Grant
    Filed: October 17, 2017
    Date of Patent: April 23, 2019
    Inventor: Amy J. Reisinger
  • Patent number: 10254293
    Abstract: The invention is directed to methods of using novel Babesia antigen peptides in detecting Babesia spp. in a sample. The methods may be adapted to assays suitable for high blood volume screening, use for clinical diagnosis of patients with babesiosis, or assaying blood contaminated with Babesia spp., such as B. microti.
    Type: Grant
    Filed: October 22, 2012
    Date of Patent: April 9, 2019
    Assignee: IMMUNETICS, INC.
    Inventors: James L. Erwin, III, Neil X. Krueger, Andrew E. Levin
  • Patent number: 10209239
    Abstract: Biosensors are disclosed for detecting ligand binding at ectopic Olfactory Receptors. Methods of identifying novel ectopic Olfactory Receptors are also disclosed. Ligands for ectopic Olfactory Receptors are disclosed as well as methods for using these ligands to interact with ectopic Olfactory Receptors, including the use of such ligands in the treatment and/or mitigation of disease conditions.
    Type: Grant
    Filed: March 21, 2018
    Date of Patent: February 19, 2019
    Assignee: Aromyx Corporation
    Inventors: Chris Hanson, William Harries
  • Patent number: 10138278
    Abstract: Disclosed is a functional derivative of a Photoactive Yellow Protein (PYP), or a functional fragment thereof, for fluorescently labelling particles, e.g. proteins, or surfaces, which is capable of binding reversibly a fluorogenic chromophore of formula (I), and which is capable of enhancing the brightness of the fluorogenic chromophore upon complexation thereto; and of inducing the spectral shift of the fluorogenic chromophore through the ionization of an auxochromic group thereof.
    Type: Grant
    Filed: July 3, 2015
    Date of Patent: November 27, 2018
    Assignees: PARIS SCIENCES ET LETTRES—QUARTIER LATIN, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE(CNRS), UNIVERSITE PIERRE ET MARIE CURIE—PARIS 6 (UPMC)
    Inventors: Arnaud Gautier, Ludovic Jullien
  • Patent number: 10088481
    Abstract: The present invention describes a liquid direct fluorescence antibody assay that is rapid and sensitive to detect respiratory virus in infected cells. The assay includes centrifugation of the specimen, incubation of sample and reagents in solution, and detection of the absence or presence of respiratory virus. Sapogenin is used as a detergent to permeabilize the cells for entry of the monoclonal antibodies to react with intracellular antigens. The cells are stained with fluorescently labeled monoclonal antibodies against the viral antigens along with a background stain and a fluorescent nuclear stain. This counter staining decreases background and allows co-localization of antigen and nuclear structures for enhanced detection.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: October 2, 2018
    Assignee: Diagnostic Hybrids, Inc.
    Inventors: David R. Scholl, James L. Brown, Joseph A. Jollick, Jr., Ronald Lollar
  • Patent number: 10082503
    Abstract: Method, system and an article of manufacture for clustering and thereby identifying predefined antigens reactive with undetermined immunoglobulins of sera derived from patient subjects in need of diagnosis of disease or monitoring of treatment.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: September 25, 2018
    Assignee: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    Inventors: Irun R. Cohen, Eytan Domany, Francisco Javier Quintana, Guy Hed, Gad Getz
  • Patent number: 10041951
    Abstract: An imaging probe can include a photoluminescent carbon nanostructure configured to emit a wavelength of light detectable through living tissue, and a targeting moiety including a first binding partner configured to interact with a second binding partner.
    Type: Grant
    Filed: January 31, 2013
    Date of Patent: August 7, 2018
    Assignee: Massachusetts Institute of Technology
    Inventors: Hyunjung Yi, Debadyuti Ghosh, Jifa Qi, Angela M. Belcher, Michael S. Strano, Neelkanth M. Bardhan
  • Patent number: 10041042
    Abstract: Disclosed herein are methods, kits, and compositions for medical imaging relating to fluorescent dyes entrapped in erythrocytes. Also disclosed therein are methods, and compositions further comprising erythrocytes entrapping at least one therapeutically active agent, as well as methods for releasing the entrapped therapeutically active agent(s). Disclosed herein also are methods for preparation of the cells entrapping dye and therapeutically active agent(s) in a freeze-dried form that makes them readily available and easy to use in a clinical environment.
    Type: Grant
    Filed: February 10, 2014
    Date of Patent: August 7, 2018
    Assignee: NOVADAQ TECHNOLOGIES ULC
    Inventor: Robert W. Flower
  • Patent number: 10036011
    Abstract: The present invention discloses methods of applications of indole-3-propionic acid, L-carnitine and O-acetyl-L-carnitine in one or more different reactive steps of a sequencing-by-synthesis workflow. The reactive steps employing these compounds include, but are not limited to, cleaving, imaging, incorporating bases and washing. The use of these new compounds provides improved sequencing performance including, but not limited to, lower error rates, higher sequence outputs and/or longer read lengths.
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: July 31, 2018
    Assignee: QIAGEN Waltham, INC.
    Inventor: Luisa Andruzzi
  • Patent number: 10036098
    Abstract: A method for automated in situ determining an analyte content of a liquid sample by means of a bioanalyzer, wherein a measurement duct has at least one substrate, comprising a repeatedly performable sequence of steps as follows: (i) preparing a sensor matrix, which has a plurality of receptors, which bind the analyte and/or a further target molecule, or bring about a chemical conversion of the analyte or of the further target molecule, leading through the measurement duct a preparation solution of at least a first chemical species, wherein a plurality of the first chemical species are bound on the substrate via the functional group binding on the substrate, wherein the other functional group of the plurality of the first chemical species bound on the substrate serves as a receptor or for subsequent binding of a receptor; (ii) leading the liquid sample, through the measurement duct, wherein analyte contained in the liquid sample or in the liquid to be measured, and/or other target molecules contained in the li
    Type: Grant
    Filed: August 26, 2011
    Date of Patent: July 31, 2018
    Assignee: Endress+Hauser Conducta GmbH+Co. KG
    Inventors: Michael Hanko, Angela Eubisch, Axel Fikus
  • Patent number: 10012648
    Abstract: The present invention relates to the discovery that measurement of the level of cytochrome c (Cyt-C) in the plasma can be used as a diagnostic signature to predict antiretroviral therapy (ART) toxicity in human immunodeficiency virus (HIV) infected patients. Thus, in various embodiments described herein, the methods of the invention relate to methods of diagnosing a HIV patient with ART toxicity, methods of predicting a patient's risk of having or developing toxicity for ART, methods of assessing if a patient will benefit from a change in the treatment strategies by adjusting the dosage and/or changing the medication or even terminating of ART, and methods of predicting antiretroviral drugs propensity for causing mitochondrial toxicity. Furthermore, the invention encompasses a diagnostic kit for carrying out the aforementioned methods.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: July 3, 2018
    Assignee: Yale University
    Inventors: Elijah Paintsil, Allison Langs-Barlow
  • Patent number: 9967747
    Abstract: Systems are provided that allow users to access resources in a manner that addresses inherent deficiencies in existing authentication systems. During a typical authentication process, the system may connect the user to one or more authenticators in real time through a variety of communications channels so that the authenticators may verify that the user is who he/she purports to be. In this way, a user may be authenticated and allowed to complete transactions that require access to protected resources/transactions. In some embodiments, the system may automatically identify authenticators for a user via an onboarding process by searching the user's electronic files, accessing social and professional networking sites, searching one or more credit reporting databases, or other such means.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: May 8, 2018
    Assignee: Rivetz Corp.
    Inventors: Bradley N. Rotter, Pavan K. Muddana
  • Patent number: 9951142
    Abstract: The present invention provides methods and compositions for determining sepsis in an individual. Specifically, the present invention provides for antibodies of fragments thereof that specifically bind to presepsin. The antibodies of the present invention may be monoclonal antibodies, and they may specifically bind to a particular epitope of presepsin. The present invention further provides methods of using such antibodies to determine whether an individual has sepsis, and kits comprising the disclosed antibodies.
    Type: Grant
    Filed: February 25, 2015
    Date of Patent: April 24, 2018
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventor: Kamon Shirakawa
  • Patent number: 9914974
    Abstract: Embodiments of the present invention concern methods and compositions related to detection of ovarian cancer, including detection of the stage of ovarian cancer, in some cases. In particular, the invention encompasses use of expression of TFAP2A and in some embodiments CA125 and/or E2F5 to identify ovarian cancer, including detecting mRNA and/or protein levels of the respective gene products. Kits for detection of ovarian cancer are also described.
    Type: Grant
    Filed: June 9, 2015
    Date of Patent: March 13, 2018
    Assignee: King Abdullah University of Science and Technology
    Inventors: Vladimir Bajic, Mandeep Kaur
  • Patent number: 9817006
    Abstract: The present invention provides a rapid, sensitive method for forensic drug testing in a post-mortem subject using oral fluid collected from the post-mortem subject. The method comprises collecting a sample of oral fluid from a post-mortem subject, analyzing the oral fluid sample qualitatively to detect the presence of one or more non-naturally occurring drugs, analyzing the oral fluid sample quantitatively to determine concentration of the one or more non-naturally occurring drugs in the post-mortem subject, and identifying the one or more non-naturally occurring drugs in the post-mortem subject. The detection and quantification in oral fluid is more sensitive and faster than detection and quantification of the non-naturally occurring drugs in blood, urine, bile, and liver tissue collected from the same post-mortem subject. Further, the qualitative and quantitative results are obtained in as little as three hours.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: November 14, 2017
    Inventor: Amy J. Reisinger
  • Patent number: 9708648
    Abstract: The disclosed Hi-C protocol can identify genomic loci that are spatially co-located in vivo. These spatial co-locations may include, but are not limited to, intrachromosomal interactions and/or interchromosomal interactions. Hi-C techniques may be applied to many different scales of interest. For example, on a large scale, Hi-C techniques can be used to identify long-range interactions between distant genomic loci.
    Type: Grant
    Filed: April 25, 2016
    Date of Patent: July 18, 2017
    Assignees: University of Massachusetts, Massachusetts Institute of Technology, President and Fellows of Harvard College, Whitehead Institute for Biomedical Research
    Inventors: Job Dekker, Erez Lieberman Aiden, Nynke Van Berkum, Andreas Gnirke, Eric Lander, Chad Nusbaum, Louise Williams, Alexandre Melnikov, Georgia Giannoukos
  • Patent number: 9696298
    Abstract: Provided is a composition comprising an analyte bound covalently or through a first binding pair to a polymer. In this composition, the analyte is less than about 2000 MW; the polymer further comprises more than one signal or first member of a second binding pair; and the analyte is not a member of the first binding pair or the second binding pair. Also provided is an assay for an analyte. The assay comprises: combining a sample suspected of containing the analyte with the above-described composition and a binding agent that binds to the analyte; and detecting the signal or the first member of the second binding pair that is bound to the binding agent. Additionally provided is a multisignal labeling reagent comprising a first polymer covalently bound to (a) a reactive group or a first member of a first binding pair, and (b) more than one digoxigenin molecule.
    Type: Grant
    Filed: July 24, 2012
    Date of Patent: July 4, 2017
    Assignee: Enzo Life Sciences, Inc.
    Inventors: Jack Coleman, Maciej Szczepanik, Richard Jin
  • Patent number: 9689880
    Abstract: Disclosed are methods of identifying subjects with arteriovascular disease, subjects at risk for developing arteriovascular disease, methods of differentially diagnosing diseases associated with arteriovascular disease from other diseases or within sub-classifications of arteriovascular disease, methods of evaluating the risk of arteriovascular events in patients with arteriovascular disease, methods of evaluating the effectiveness of treatments in subjects with arteriovascular disease, and methods of selecting therapies for treating arteriovascular disease.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: June 27, 2017
    Assignee: TRUE HEALTH IP LLC
    Inventors: Mickey S. Urdea, Michael P. McKenna, Patrick A. Arensdorf
  • Patent number: 9664673
    Abstract: Apparatus for performing an assay to detect the presence of an analyte in a test sample. A housing defines a slot for receiving a sample collector, and a capsule contains a buffer liquid, the capsule being sealed by an openable lid, and being connected to the housing such that insertion of a sample collector into the slot causes the lid to open releasing the buffer liquid into the slot. The housing further defines an incubation chamber containing or configured to receive a reagent, and an aperture permitting liquid communication between the slot and the incubation chamber. The apparatus comprises one or more test elements, a substantially liquid tight sealing member separating the incubation chamber and the test element(s), and an activation mechanism operable to open the liquid tight sealing member thereby bringing at least a portion of the or each test element into liquid communication with the incubation chamber.
    Type: Grant
    Filed: October 8, 2014
    Date of Patent: May 30, 2017
    Assignee: ALERE TOXICOLOGY PLC
    Inventors: Alan Pang, Gordon Jowett, Barry Lillis, Jack Fairbank
  • Patent number: 9632078
    Abstract: The invention discloses a method for detecting at least one antigen, comprising the following steps: providing magnetic beads, which are coated with antibodies specific for at least one antigen to be detected; bringing the magnetic beads in contact with a washing buffer that comprises at least 8% BSA and incubating the mixture with a sample; isolating the magnetic beads by means of magnetic separator; and detecting the antigens bound to the magnetic beads by the antibodies. Washing buffers, primers, kits and devices that can be used for said methods are also disclosed.
    Type: Grant
    Filed: July 6, 2010
    Date of Patent: April 25, 2017
    Assignee: AIRBUS DEFENCE AND SPACE GMBH
    Inventors: Ulrich Reidt, Alois Friedberger, Christoph Heller, Hero Brahms
  • Patent number: 9632069
    Abstract: Embodiments of the invention include integrated systems and methods of evaluating cannabis and cannabinoid products for public safety, quality control and quality assurance purposes for research and public use purposes. Embodiments of the invention facilitate suppliers and consumers of a cannabis and/or cannabinoid product to evaluate the origin, efficacy, potency, and quality of the product. Embodiments of the invention also include cannabis processing center where samples of the products are analyzed for research studies to test and set parameters for third parties. Embodiments of the invention include, for example, analyzing cannabis products to determine quality and quantity of desired components and undesired components, determining concentrations of cannabinoids in the product, and comparing measures of components in the product against regulations.
    Type: Grant
    Filed: June 23, 2014
    Date of Patent: April 25, 2017
    Assignee: VYRIPHARM LLC
    Inventors: Elias Bernard Jackson, Jr., Jerry L. Bryant, Jr.
  • Patent number: 9588129
    Abstract: A method of detecting a disease associated with abnormal protein aggregation in a subject is provided, the method comprising (a) contacting leukocytes from the subject with a probe that binds to pathogenic protein aggregates, and (b) detecting the probe bound to the pathogenic protein aggregates, wherein the presence of pathogenic protein aggregates in the leukocytes is indicative that the subject has a disease associated with abnormal protein aggregation. In one embodiment, the disease is Alzheimer's disease or mild cognitive impairment.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: March 7, 2017
    Assignee: Amira Medical Technologies Inc.
    Inventors: Peter Stys, Shigeki Tsutsui
  • Patent number: 9568481
    Abstract: Measurement of circulating ST2 and/or IL-33 concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, and the detection of severe disease.
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: February 14, 2017
    Assignee: Critical Care Diagnostics, Inc.
    Inventors: James V. Snider, Sven Jacobson
  • Patent number: 9555114
    Abstract: A method of controlled in vivo drug delivery is provided. A porous silicon matrix having pores sized and configured to admit to trap and then release a predetermined molecular complex with a predetermined dose-time profile is selected. The matrix contains the predetermined molecular complex so that the predetermined molecular complex is disposed within the pores of the porous silicon matrix. The matrix is introduced into a human body. The drug releases according the dose-time profile. The introduction can be via transdermal introduction, intramuscular injection, intravenous introduction, surgical implantation, inhalation, and oral ingestion.
    Type: Grant
    Filed: September 19, 2014
    Date of Patent: January 31, 2017
    Assignee: The Regents of the University of California
    Inventors: Michael J. Sailor, Guarav Abbi, Boyce E. Collins, Keiki-Pua S. Dancil
  • Patent number: 9551703
    Abstract: The invention features compositions and methods that are useful for precisely determining the amount of one or more analytes present in a sample. In one aspect, the invention provides a composition for measuring the abundance of one or more target analytes in a sample, where the composition contains a set of detection units for each analyte fixed to a substrate (e.g., a membrane, bead, filter, chip, polymer-based film or glass slide, or other printable surface), where each detection unit contains a discrete amount of a capture agent that specifically binds the target analyte, and the amount of capturing agent varies over the set to form a concentration gradient.
    Type: Grant
    Filed: August 4, 2010
    Date of Patent: January 24, 2017
    Assignee: The Johns Hopkins University
    Inventors: Zhen Zhang, Daniel W. Chan
  • Patent number: 9551694
    Abstract: A micro titer plate comprising a number of wells filled with separation matrix. According to the invention the volume of the separation matrix is varied between at least some of the wells.
    Type: Grant
    Filed: October 7, 2009
    Date of Patent: January 24, 2017
    Assignee: GE Healthcare BioProcess R&D AB
    Inventor: Karol Lacki
  • Patent number: 9547016
    Abstract: The present invention relates to a method for determining the amount of a physiologically acceptable polymer molecule bound to a protein, an antibody or other composition being capable of specifically binding to a physiologically acceptable polymer molecule, and a kit containing said antibody or composition.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: January 17, 2017
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Peter Turecek, Juergen Siekmann, Alfred Weber, Herbert Gritsch, Katalin Varadi, Susanne Vejda
  • Patent number: 9500506
    Abstract: The invention provides a system and method for determining fluid flow in a fluid pipe network. One or more markers are installed a various locations on the pipe network. Each marker generates an alteration in one or both of an initial fluid flow and an initial fluid pressure at the marking location of the marker. The alteration is characterized by one or more parameters whose values are indicative of one or both of the initial fluid flow and the initial fluid pressure at the marking location of the marker. One or more sensors are also installed on the network that detect one or both of a fluid pressure or a fluid flow rate at one or more sensing locations in the pipe network and generate a signal indicative of one or both of the fluid pressure and the fluid flow rate at the sensing location of the sensor. A processor analyzes the signal generated by each sensor to determine one or both of the initial fluid flow rate and initial fluid pressure at the marking locations.
    Type: Grant
    Filed: March 20, 2012
    Date of Patent: November 22, 2016
    Assignee: WATERSIGN LTD
    Inventor: Dan Dayan Rahamim
  • Patent number: 9500640
    Abstract: An assay for Alzheimer's disease pathology (AD) in a living patient is disclosed wherein an amount of ?7nAChR-FLNA, TLR4-FLNA and/or ?7nAChR-A?42 complex present as a protein-protein complex in a sample is determined and compared to the amount in a standard sample from a person free of AD pathology. Use of one or more of those ratios provides an assay predictive of prognosis for treatment with a medicament in which the amount of an above protein complex is determined and compared to an amount determined in the presence of a medicament that binds to a FLNA pentapeptide and contains at least four of the six pharmacophores of FIGS. 7-12. An amount of protein complex determined in the presence of the medicament less than the first determined amount indicates a favorable treatment prognosis.
    Type: Grant
    Filed: July 18, 2013
    Date of Patent: November 22, 2016
    Assignee: Pain Therapeutics, Inc.
    Inventors: Hoau-Yan Wang, Lindsay Burns Barbier
  • Patent number: 9488600
    Abstract: An electrically conductive nanoscale sensor includes a nanoscale pore that may be employed as a first antenna to provide precise localized measurements of the impedance-altering characteristics of a molecule such as DNA or RNA or the like passing through the pore. The use of radiofrequency measurements via a second antenna communicating with the first antenna promises high-speed analysis of long molecules (polymers).
    Type: Grant
    Filed: July 28, 2014
    Date of Patent: November 8, 2016
    Assignees: Wisconsin Alumni Research Foundation, University of Hamburg
    Inventors: Robert H. Blick, Abhishek Bhat, Paul Gwozdz
  • Patent number: 9482615
    Abstract: Embodiments encompass a single-molecule detection system and methods of using the detection system to detect an object. Further, embodiments encompass a detection system comprising a movable light coupler, a waveguide, and a light detector. Embodiments further encompass methods of single-molecule detection, including methods of single-molecule nucleic acid sequencing.
    Type: Grant
    Filed: March 11, 2011
    Date of Patent: November 1, 2016
    Assignee: Industrial Technology Research Institute
    Inventors: Chung-Fan Chiou, Ying-Chih Pu, Chao-Chi Pan, Chih-Tsung Shih, Ming-Chia Li, Chein-Shiu Kuo, Hung-Chi Chien, Chang-Sheng Chu
  • Patent number: 9476884
    Abstract: The present invention discloses a transcription activator-like effector-based strategy, termed “TALEColor”, for labeling specific repetitive DNA sequences in human chromosomes. TALEs were custom designed for human telomeric repeats and fused with any of numerous fluorescent proteins (FPs). TALE-telomere-FP fusion proteins were used to detect telomeric sequence in both living cells and fixed cells. Using human cells with different average telomere lengths, TALEColor signals correlated positively with telomere length. TALEs were also designed to detect centromeric sequences unique to specific chromosomes, enabling localization of these specific human chromosomes in live cells. These methods may have significant potential both for basic chromosome and genome research as well as in clinical applications.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: October 25, 2016
    Assignee: University of Massachusetts
    Inventor: Hanhui Ma
  • Patent number: 9464324
    Abstract: Methods are disclosed for determining the prognosis of a subject with an adenocarcinoma in an organ, such as the lung. The methods can include quantitating expression of a plurality of cytokines of interest, such as IL-1a, IL-1b, IL-2, IL-8, IL-10, IL-12, IL-15, IFN-? and TNF-a in the adenocarcinoma and in non-cancerous tissue in the organ. Altered expression of IL-1a, IL-1b, IL-2, IL-8, IL-10, IL-12, IL-15, IFN-? and TNF-a in the adenocarcinoma as compared to a control and in non-cancerous tissue in the organ as compared to a control determines the prognosis for the subject. Methods for determining if a therapeutic agent is effective as an anti-cancer agent are also disclosed.
    Type: Grant
    Filed: July 16, 2007
    Date of Patent: October 11, 2016
    Assignee: The United States of America as represented by the Secretary, DHHS
    Inventors: Curtis C. Harris, Masahiro Seike, Xin Wei Wang
  • Patent number: 9434985
    Abstract: The disclosed Hi-C protocol can identify genomic loci that are spatially co-located in vivo. These spatial co-locations may include, but are not limited to, intrachromosomal interactions and/or interchromosomal interactions. Hi-C techniques may be applied to many different scales of interest. For example, on a large scale, Hi-C techniques can be used to identify long-range interactions between distant genomic loci.
    Type: Grant
    Filed: September 22, 2009
    Date of Patent: September 6, 2016
    Assignees: University of Massachusetts, Massachusetts Institute Of Technology, President And Fellows Of Harvard College, Whitehead Institute For Biomedical Research
    Inventors: Job Dekker, Erez Lieberman, Nynke Van Berkum, Andreas Gnirke, Eric Lander, Chad Nusbaum, Louise Williams, Alexandre Melnikov, Georgia Giannoukos